Scalper1 News
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical companies. While IBD has no greater ability than anyone else to predict the future, here are four biotech stocks that have been named as possible targets on the Street, with stock-moving results. Scalper1 News
Scalper1 News